Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Manabu Hirai, MDPhD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, MD PhD, Erina Sakamoto, MD PhD

Blood (2015) 126 (23): 1688.

https://doi.org/10.1182/blood.V126.23.1688.1688

Published: 2015

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Manabu Hirai, MDPhD, Mizuki Aimoto, MD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Erina Sakamoto, MD PhD, Hirohisa Nakamae, Masayuki Hino, MD PhD

Blood (2014) 124 (21): 3260.

https://doi.org/10.1182/blood.V124.21.3260.3260

Published: 2014

Journal Articles

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Manabu Hirai, MD, PHD, Takahiko Nakane, M.D., Ph.D., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, M.D., Erina Sakamoto, MD, PHD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD

Blood (2013) 122 (21): 1536.

https://doi.org/10.1182/blood.V122.21.1536.1536

Published: 2013

Journal Articles

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Manabu Hirai, MD, PHD, Ryousuke Yamamura, MD, PHD, Hirohisa Nakamae, MD, PhD, Yoshiki Terada, MD., PhD., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Hiroyoshi Ichihara, MD, PHD, Erina Sakamoto, MD, PHD, Masayuki Hino

Blood (2012) 120 (21): 1187.

https://doi.org/10.1182/blood.V120.21.1187.1187

Published: 2012

Journal Articles

The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients

Yoshiki Terada, MD, PhD, Hirohisa Nakamae, MD, PhD, Ran Moriguchi, MD, Hiroshi Kanashima, MD, PhD, Erina Sakamoto, MD, PhD, Dai Momose, MD, Mizuki Aimoto, MD, Shuichirou Okamoto, MD, Eri Wada, MD, Hideo Koh, MD, Takahiko Nakane, MD, Yasunobu Takeoka, MD, Ki- Ryang Koh, MD, PhD, Takahisa Yamane, MD, PhD, Yoshitaka Nakao, MD, PhD, Kensuke Ohta, MD, PhD, Atsuko Mugitani, MD, PhD, Hirofumi Teshima, MD, PhD, Masayuki Hino, MD, PhD

Blood (2008) 112 (11): 4931.

https://doi.org/10.1182/blood.V112.11.4931.4931

Published: 2008

Journal Articles

Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor.

Erina Sakamoto, MD, Hirohisa Nakamae, MD, Ki Ryang Koh, MD, Takahisa Yamane, MD, Masayuki Hino, MD

Blood (2006) 108 (11): 4767.

https://doi.org/10.1182/blood.V108.11.4767.4767

Published: 2006

Journal Articles

Risk Factor Analysis for Thrombotic Microangiopathy after Reduced Intensity or Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.

Hirohisa Nakamae, MD, PhD, Takahisa Yamane, MD, PhD, Hagihara Kiyoyuki, MD., PhD., Yasunobu Takeoka, MD., Erina Sakamoto, MD., PhD., Takahiko Nakane, MD., Mika Nakamae, MD., PhD., Ki-Ryang Koh, MD., PhD., Kensuke Ohta, MD., PhD., Masayuki Hino, MD., PhD.

Blood (2005) 106 (11): 1775.

https://doi.org/10.1182/blood.V106.11.1775.1775

Published: 2005

NARROW

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients

Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor.

Risk Factor Analysis for Thrombotic Microangiopathy after Reduced Intensity or Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients

Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor.

Risk Factor Analysis for Thrombotic Microangiopathy after Reduced Intensity or Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only